The US Food and Drugs Administration (FDA) approved dianabolic medication in March 2018, allowing it to treat a range of conditions including asthma and rheumatoid arthritis.
However, the product is still not ready for use in the UK.
In the UK, patients have to apply for approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) before they can buy it.
According to the MHRA website, the drug can help patients who have an allergy to dianacetic acid (DA), a chemical found in some foods.DA, however, is not recognised by the US Food Standards Agency (FSA) as a medicine and therefore cannot be sold to patients.
This means that the drug is available to the public only in the US.
However the drug has now been approved for sale in the United Kingdom and is available for purchase from pharmacies.
Dianabol has been developed by Merck in partnership with UK pharmaceutical giant Bristol-Myers Squibb.
The drug is marketed as a “treatments” and is currently being tested on patients in the USA.
In 2018, the UK also approved diclofenac, a drug used to treat depression and anxiety.
The FDA approved diaclofinac in June 2018 and the UK’s Medicines & Healthcare Products Regulatory Agency said it was “commercially available and fully regulated”.
In the US, the FDA said it “will continue to monitor dicliconac’s effectiveness in preventing and treating certain chronic illnesses”.
It said it will continue to review the safety and efficacy of other products.
Dr Andrew Dickson, who chairs the MHSA’s Scientific Advisory Committee, said the company has been working closely with the FDA and the British government on diclosan, which is currently in clinical trials.
“In addition to the potential for this drug to benefit patients with severe allergies, we also hope that the UK and the US will develop similar products,” he said.
“There is no shortage of companies and drugs which could benefit from the development of new therapies for these conditions, including diclonal.
The UK Medicine & Healthcare products Board (MHBC) said in a statement that it has been in close contact with Bristol-MYERS SQUIBB and Merck about the new drug.”
We believe this product is a safe, effective treatment for the chronic condition of chronic inflammation and we look forward to a smooth launch of the new product,” the board said.
Dr Dickson said the new diclocar is the latest in a line of drugs that have been approved in the past decade to treat serious allergies.”
Diacloprid was introduced to the UK market in 2000 and in 2014, the first diclcobra (DA) was approved for use as a treatment for severe allergic rhinitis,” he added.”
As with all new medicines, the long term benefits of diclorol are unknown.
“Follow James on Twitter.